Shrinking margins and lack of new products. Get it? The market looks forward.
Its worked out for you so far but I am guessing it had nothing to do with your chart reading and more to do with the sell off of biotechs. As bear has said there are several pending news developments coming that will move this stock. If you know what the news is you can place your bet otherwise your just gambling. My guess is that good news is coming. Good luck.
JING, theres another $0.50 earned by phosteric for his repetitive post. Meanwhile another new all time high today and upgraded price target to $87 by Goldman Sachs.
He will post the exact same message again in the near future and than never defends his position. My guess is he gets paid fifty cents for every bash post. What he or whoever is paying him fails to realize is these posts have zero effect on trading and the price. 99+% of this stock is held by insiders and mutual funds. I doubt they act on these simpleton posts.
Either you are a liar or an idiot. Which is it?
"Zytiga won’t be going generic in 2016. On July 30, 2013, JNJ secured a new patent for the combination use of Zytiga and prednisone in the treatment of prostate cancer. This extends Zytiga’s patent life well into the late 2020s and pretty much erases the threat of generic Zytiga in 2016."
Your right about one thing. Research never stops. There will hopefully be new treatments for this and all other cancers. In the foreseeable future, or as you call it, a moment in time, Xtandi looks to be the treatment of growing choice. If your going to always be worrying about possible competing drugs many years away from approval you will never pull the trigger on todays winners
Closing in on a ten bagger for my remaining $8 shares, sold earlier shares anywhere from mid 40's to upper 50's for various reasons (some fun others not so fun). Waiting on the PREVAIL data and will most likely than sell half of my leftovers and will hold the remainder for the buyout. No complaints from me concerning management.
"Medivation price target raised to $89 from $70 at Citigroup
Citigroup raised its price target for Medivation shares to $89 on expectations Xtandi will beat estimates. Citi expects peak sales of $6.5B in 2026 and keeps a Buy rating on the stock."